Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery
Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
- Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
- These proceeds will be used to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025.
- “We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo® patient specific implants are achieving this goal,” stated Mike Cordonnier, CEO of Carlsmed.
- The Carlsmed implantable devices and software platforms are FDA cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.